Sanmartí R, Ruiz-Esquide V, Hernández MV. Rheumatoid arthritis: a clinical overview of new diagnostic and treatment approaches. Curr Top Med Chem. 2013;13(6):698–704.
Smolen JS, Aletaha DA, McInnes IB. Rheumatoid arthritis. Lancet. 2016;388(10055):2023–38.
Cooles FA, Isaacs JD. Pathophysiology of rheumatoid arthritis. Curr Opin Rheumatol. 2011;23(3):233–40.
European Medicines Agency. Remicade, INN-infliximab. London: European Medicines Agency; 2005.
Putrik P, Ramiro S, Kvien TK, Sokka T, Pavlova M, Uhlig T, Boonen A. Inequities in access to biologic and synthetic DMARDs across 46 European countries. Ann Rheum Dis. 2014;73:198–206.
China Food and Drug Administration. Guidelines for the development and evaluation of similar biological products. Beijing: China Food and Drug Administration; 2015.
European Medicines Agency. Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: non-clinical and clinical issues. London: European Medicines Agency; 2014.
US Food and Drug Administration. Guidance for industry: scientific considerations in demonstrating biosimilarity to a reference product. Silver Spring: US Food and Drug Administration; 2012.
World Health Organization. Guidelines on evaluation of similar biotherapeutic products. Geneva: World Health Organization; 2009.
China Food and Drug Administration. Technical guidelines for the study of human bioavailability and bioequivalence in chemical pharmaceutical preparations. Beijing: China Food and Drug Administration; 2007.
World Medical Association. Declaration of Helsinki. Ethical principles for medical research involving human subjects. Ferney-Voltaire: World Medical Association; 2001.
China Food and Drug Administration. Guideline for good clinical principles. Beijing: China Food and Drug Administration; 2016.
US Department of Health and Human Services. Common terminology criteria for adverse events (CTCAE) version 4.0. J Natl Cancer Inst. 2009;09:5410.
Smith BP, Vandenhende FR, DeSante KA, Farid NA, Welch PA, Callaghan JT, et al. Confidence interval criteria for assessment of dose proportionality. Pharm Res. 2000;17(10):1278–83.
Wolbink GJ, Voskuyl AE, Lems WF, Groot ED, Nurmohamed MT, Tak PP, et al. Relationship between serum trough infliximab levels, pretreatment C reactive protein levels, and clinical response to infliximab treatment in patients with rheumatoid arthritis. Ann Rheum Dis. 2005;64:704–7.
Mori S. A relationship between pharmacokinetics (PK) and the efficacy of infliximab for patients with rheumatoid arthritis: characterization of infliximab-resistant cases and PK-based modified therapy. Mod Rheumatol. 2007;17:83–91.
US Food and Drug Administration. Clinical pharmacology review of BLA 99–0128. Remicade Supplement. Silver Spring: US Food and Drug Administration; 1999.
Shin D, Kim Y, Kim YS, Kornicke T, Fuhr R. A randomized, phase I pharmacokinetic study comparing SB2 and infliximab reference drug (Remicade®) in healthy subjects. BioDrugs. 2015;29(6):381–8.
Danesh A, Janghorbani M, Khalatbari S. Effects of antenatal corticosteroids on maternal serum indicators of infection in women at risk for preterm delivery: a randomized trial comparing betamethasone and dexamethasone. J Res Med Sci. 2012;17(10):911–7.
Schuld A, Birkmann S, Beitinger P, Haack M, Kraus T, Dalal MA, et al. Low doses of dexamethasone affect immune parameters in the absence of immunological stimulation. Exp Clin Endocrinol Diabetes. 2006;114(6):322–8.
Liles WC, Huang JE, Llewellyn C, SenGupta D, Price TH, Dale DC. A comparative trial of granulocyte-colony-stimulating factor and dexamethasone, separately and in combination, for the mobilization of neutrophils in the peripheral blood of normal volunteers. Transfusion. 1997;37(2):182–7.
Dexamethasone sodium phosphate. Product information. 2010. https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent&id=CP-2011-PI-02528-3. Accessed 20 Sep 2018.